Search Orphan Drug Designations and Approvals
-
Generic Name: | mavorixafor |
---|---|
Date Designated: | 07/01/2022 |
Orphan Designation: | Treatment of Waldenstrom’s Macroglobulinemia |
Orphan Designation Status: | Designated |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
X4 Pharmaceuticals, Inc. 61 N Beacon St; 4th Floor Boston, Massachusetts 02134 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-